Searched for
GLAXOSMITHKLINE CONSUMER HEALTHCARE LTD.
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Buy GlaxoSmithKline Consumer Healthcare, target Rs 7,310: SharekhanBuy GlaxoSmithKline Consumer Healthcare Ltd. at a price target of Rs 7310.0 .
- Accumulate GlaxoSmithKline Consumer Healthcare, target Rs 6,797: Prabhudas LilladherAccumulate GlaxoSmithKline Consumer Healthcare Ltd. at a price target of Rs 6797.0 .
- Buy GlaxoSmithKline Consumer Healthcare, target Rs 6765 : ICICI SecuritiesBuy GlaxoSmithKline Consumer Healthcare Ltd. at a price target of Rs 6765. The stock has been trading at 25 times its FY18 earnings multipl...
- Buy GlaxoSmithKline Consumer Healthcare., target Rs 7500: Bank of America Merrill LynchBofA-ML expects a cyclical upturn in FY2016-19 after poor revenue growth in FY2016.
- GlaxoSmithKline Consumer resumes operations at Nabha plantThe company had suspended operations temporarily at factory from May 21 following disruptions by its workforce who were demanding hike in w...
- GSK Pharma completes deal with Novartis HealthcareDrug firm GlaxoSmithKline Pharmaceuticals has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis...
- Novartis India gets FIPB nod to sell OTC biz to GSK CPLNovartis India today said it has received FIPB approval to sell its OTC division to GlaxoSmithKline Consumer Pvt Ltd (GSK CPL).
- GSK Consumer Healthcare Q2 Net up 9% at Rs 160.29 croreShares of GlaxoSmithKline Consumer Healthcare were trading at Rs 5,429.95 apiece in afternoon trade, down 1.99 per cent from their previous...
- GlaxoSmithKline Consumer Healthcare Ltd India-Novartis deal won't affect business in IndiaGlaxoSmithKline Consumer Healthcare today said the global deal between GlaxoSmithKline Plc and Novartis won't affect its business in India.
- NSE to drop GlaxoSmithKline Consumer from F&O segmentNSE said it will exclude GlaxoSmithKline Consumer Healthcare from the Futures and Options segment with effect from May 30.
- GlaxoSmithKline Consumer expands Horlicks portfolioHorlicks Kesar Badaam is the fourth variant in the Horlicks portfolio; the other flavours available are Malt, Chocolate and Elaichi.
- GSK gets Sebi nod for GlaxoSmithKline Consumer open offerThe offer is scheduled to open from Jan 17, according to the announcement made by HSBC on behalf of GSK and is expected to close on January...
- GlaxoSmithKline Plc's open offer for GSKCH to start on January 17The UK-based GlaxoSmithKline Plc's open offer to acquire 31.8 per cent stake in its Indian subsidiary GlaxoSmithKline Consumer Healthcare w...
- UK-based healthcare major GlaxoSmithKline to invest Rs 5,220 cr in India subsidiaryGlaxoSmithKline today announced plans to infuse about Rs 5,220 crore in its Indian subsidiary GSKCH by increasing stake to 75% from 43.2% a...
- GSK Consumer hits record high on parent company's plan to raise its stakeGSK Consumer surged 20% to hit its record high in early trade after its parent plans to raise its stake in Indian arm to 75%.
Load More
